Oncocyte acquires Chronix Biomedical for blood-based cancer monitoring technology

Oncocyte Corporation entered a definitive agreement to acquire Chronix Biomedical, including its intellectual property and technology for blood-based immune therapy monitoring and transplant rejection testing. The deal includes Chronix's development team and lab operations in Germany.

“Oncocyte will acquire the intellectual property (IP) and technology for Chronix's TheraSure-CNI Monitor, a patented, blood-based test for immune-therapy monitoring, as well as the IP for Chronix's organ transplant technology.”globenewswire.com

• 1 source
• globenewswire.comOncocyte Announces Definitive Agreement to Acquire ChronixOncocyte CorporationFeb 2, 2021

Summarized from public sources; check the original articles before acting on it.